Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | More
 
or
Watchlist | Portfolio
Site News
Contact
Market:

Gsk Plc (GSK.LN)

Gsk Plc (GSK.LN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [LSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [LSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 72,731,559
  • Shares Outstanding, K 4,078,024
  • Annual Sales, $ 30,328 M
  • Annual Income, $ 4,928 M
  • 60-Month Beta N/A
  • Price/Sales 2.39
  • Price/Cash Flow 9.57
  • Price/Book 5.26
Trade GSK.LN with:
  • Price/Earnings ttm 16.39
  • Earnings Per Share ttm 1.09
  • Most Recent Earnings $0.25 on 05/01/24
  • Latest Earnings Date N/A
  • Annual Dividend & Yield 0.58 (3.36%)
  • Most Recent Dividend 0.150 on 05/16/24
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
1,575.000 +12.70%
on 04/19/24
1,823.500 -2.66%
on 05/16/24
+185.000 (+11.64%)
since 04/17/24
3-Month
1,575.000 +12.70%
on 04/19/24
1,823.500 -2.66%
on 05/16/24
+98.600 (+5.88%)
since 02/16/24
52-Week
1,302.600 +36.27%
on 07/11/23
1,823.500 -2.66%
on 05/16/24
+332.600 (+23.06%)
since 05/17/23
Free Barchart Webinars! Live educational sessions using site features to explore today's markets.

Most Recent Stories

More News
Is This a Setback for Moderna? Motley Fool - Tue May 14, 5:35AM CDT

Moderna's shares slipped after the company announced the delay.

PFE : 28.64 (-0.97%)
GSK.LN : 1,775.000 (-0.48%)
MRNA : 132.90 (+0.17%)
Drug Patents
US challenges 'bogus' patents on Ozempic and other drugs in effort to spur competition Associated Press - Tue Apr 30, 4:36PM CDT

The Federal Trade Commission is challenging patents on 20 brand-name drugs, including the blockbuster weight-loss injection Ozempic

AZN.LN : 12,110.002 (-0.46%)
AZN : 76.90 (-0.18%)
GSK.LN : 1,775.000 (-0.48%)
GSK : 44.98 (+0.22%)
Missed Out on Eli Lilly? 2 Healthcare Stocks With Big Catalysts on the Horizon. Motley Fool - Tue Apr 9, 5:35AM CDT

These companies are close to launching new products that could supercharge revenue.

LLY : 770.00 (-0.15%)
PFE : 28.64 (-0.97%)
GSK.LN : 1,775.000 (-0.48%)
MRNA : 132.90 (+0.17%)
VRTX : 445.21 (+1.04%)
RSV Drug
Babies should get recently approved drug for RSV, CDC says Associated Press - Thu Aug 3, 2023

U.S. health officials are recommending that babies get a recently approved drug to protect them against a respiratory virus

PFE : 28.64 (-0.97%)
GSK.LN : 1,775.000 (-0.48%)
GSK : 44.98 (+0.22%)
AZN.LN : 12,110.002 (-0.46%)
AZN : 76.90 (-0.18%)
Stock-exchange announcement - For media and investors only - GSK completes acquisition of BELLUS Health Newswire.ca - Wed Jun 28, 2023

/CNW/ - GSK plc (LSE: GSK) (NYSE: GSK) and BELLUS Health Inc. (TSX: BLU) NASDAQ: BLU) today announced GSK has completed the acquisition of BELLUS, a...

BLU : 14.74 (unch)
GSK.LN : 1,775.000 (-0.48%)
GSK : 44.98 (+0.22%)
BLU.TO : 19.48 (-0.10%)
Author
ImmunoGen Nearly Triples on Ovarian Cancer Drug Phase 3 Results MarketBeat - Mon May 8, 2023

Commercial-state biotechnology company ImmunoGen Inc. (NASDAQ: IMGN) shares more than doubled on phase 3 clinical trial results. Its ovarian cancer drug

SGEN : 228.74 (-0.07%)
AZN : 76.90 (-0.18%)
IMGN : 31.23 (unch)
GSK : 44.98 (+0.22%)
GSK.LN : 1,775.000 (-0.48%)
PFE : 28.64 (-0.97%)
International Healthcare Week returns to showcase Hong Kong's strengths in healthcare innovation and investment ACN Newswire - Thu May 4, 2023

International Healthcare Week returns to showcase Hong Kong's strengths in healthcare innovation and investment

FOSUF : 0.5350 (+1.94%)
FOSUY : 14.5300 (+1.25%)
GSK.LN : 1,775.000 (-0.48%)
GSK : 44.98 (+0.22%)
JNJ : 154.64 (+0.23%)
GSK reaches agreement to acquire late-stage biopharmaceutical company BELLUS Health Business Wire - Tue Apr 18, 2023

GSK plc (LSE/NYSE: GSK) and BELLUS Health Inc. (TSX/NASDAQ: BLU) today announced that they have entered into an agreement under which GSK will acquire BELLUS, a Canada-based, late-stage biopharmaceutical...

BLU : 14.74 (unch)
GSK : 44.98 (+0.22%)
GSK.LN : 1,775.000 (-0.48%)
BLU.TO : 19.48 (-0.10%)
Author
Back from the Dead, IBM’s Watson AI is Alive and Re-Emerging MarketBeat - Mon Apr 10, 2023

While artificial intelligence (AI) seems to have come around full circle in 2023 as ChatGPT finally lit the fuse for full-blown mainstream adoption, Internat

IBM : 169.03 (+0.04%)
GOOG : 177.29 (+1.06%)
GOOGL : 176.06 (+1.08%)
GM : 45.76 (-0.24%)
GMM-U.TO : 43.32 (-1.23%)
GSK : 44.98 (+0.22%)
GSK.LN : 1,775.000 (-0.48%)
MSFT : 420.21 (-0.19%)
WWE : 100.65 (+2.65%)
Author
Schrodinger is an AI-Powered Drug Discovery Developer to Watch MarketBeat - Wed Mar 8, 2023

Drug discovery software developer Schrodinger Inc. (NASDAQ: SDGR) stock has been trying to recover after plummeting over 80% off its all-time high of $117

SDGR : 22.76 (-0.61%)
AZN.LN : 12,110.002 (-0.46%)
AZN : 76.90 (-0.18%)
AZNCF : 155.2600 (-0.30%)
LLY : 770.00 (-0.15%)
GSK : 44.98 (+0.22%)
GSK.LN : 1,775.000 (-0.48%)
ON : 73.17 (+0.23%)
PFE : 28.64 (-0.97%)
MRK : 131.19 (+0.24%)
More news for this symbol

Barchart Technical Opinion

Strong buy

The Barchart Technical Opinion rating is a 100% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Key Turning Points

3rd Resistance Point 1,796.500
2nd Resistance Point 1,788.000
1st Resistance Point 1,781.500
Last Price 1,775.000
1st Support Level 1,766.500
2nd Support Level 1,758.000
3rd Support Level 1,751.500

See More

52-Week High 1,823.500
Last Price 1,775.000
Fibonacci 61.8% 1,624.516
Fibonacci 50% 1,563.050
Fibonacci 38.2% 1,501.584
52-Week Low 1,302.600

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot